A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma

Investigational New Drugs

Volumn 25, Issue 3, 2007, Pages 247-252

  Kefford, Richard ^a   Beith, Jane McNeil ^b   Van Hazel, Guy Arthur ^c   Millward, Michael ^b   Trotter, James Marshall ^d   Wyld, David Keith ^e   Kusic, Rada ^a   Shreeniwas, Revati ^f   Morganti, Adele ^f   Ballmer, Andrea ^f   Segal, Eleonor ^f   Nayler, Oliver ^f   Clozel, Martine ^f  

^a WESTMEAD HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Perth Oncology Group   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Bosentan; Endothelin receptor; Metastatic melanoma

Indexed keywords

ALKALINE PHOSPHATASE; BOSENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BACKACHE; BLEEDING DISORDER; BRAIN METASTASIS; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; JAUNDICE; LIVER FUNCTION; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SOLID TUMOR; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AUSTRALIA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTORS, ENDOTHELIN; RNA, MESSENGER; SKIN NEOPLASMS; SULFONAMIDES; TABLETS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34248667859     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9014-7     Document Type: Article

References (25)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton AJr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
2. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687-701
3. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759
4. Khayat D, Meric J-B, Rixe O (2004) Systemic chemotherapy and biochemotherapy for non-resected and metastatic melanoma. In: Thompson JF, Morton DL, Kroon BBR (eds) Textbook of Melanoma. Martin Dunitz, London, pp 586-601
5. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J Clin Oncol 22:1118-1125
6. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166
7. Millward MJ, Bedikian AY, Conry RM, Gore ME, Pehamberger HE, Sterry W, Pavlick AC, De Conti RC, Gordon D, Itri LM (2004) Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival. (Abstract 7505). In: Proceedings of the American Society of clinical oncology (ASCO), New Orleans, 2004 (Post-Meeting Edition) J Clin Oncol 22
8. Baynash AG, Hosoda K, Giaid A, Richardson JA, Emoto N, Hammer RE, Yanagisawa M (1994) Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 79:1277-1285
9. Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, Giaid A, Yanagisawa M (1994) Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79:1267-1276
10. Ceccherini I, Zhang AL, Matera I, Yang G, Devoto M, Romeo G, Cass DT (1995) Interstitial deletion of the endothelin-B receptor gene in the spotting lethal (sl) rat. Hum Mol Genet 4:2089-2096
11. Lahav R, Ziller C, Dupin E, Le Douarin NM (1996) Endothelin 3 promotes neural crest cell proliferation and mediates a vast increase in melanocyte number in culture. Proc Natl Acad Sci USA 93:3892-3897
12. Imokawa G, Miyagishi M, Yada Y (1995) Endothelin-1 as a new melanogen: coordinated expression of its gene and the tyrosinase gene in UVB-exposed human epidermis. J Invest Dermatol 105:32-37
13. Jamal S, Schneider RJ (2002) UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. J Clin Invest 110:443-452
14. Mangahas CR, dela Cruz GV, Schneider RJ, Jamal S (2004) Endothelin-1 upregulates MCAM in melanocytes. J Invest Dermatol 123:1135-1139
15. Demunter A, De Wolf-Peeters C, Degreef H, Stas M, Van Den Oord JJ (2001) Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 438:485-491
16. Lahav R, Heffner G, Patterson PH (1999) An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 96:11496-11500
17. Bagnato A, Rosano L, Spinella F, Di Castro V, Tecce R, Natali PG (2004) Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 64:1436-1443
18. Sekulic A, Suresh P, Pittelkow M, Markovic S (2002) Bosentan, a novel endothelin-A and -B receptor antagonist inhibits proliferation of malignant melanoma cells (Abstract) Meeting of the American Association for Cancer Research. Mayo Clinic, Rochester, MN, USA
19. Berger Y, Chapuis Bernasconi C, Juillerat-Jeanneret L (2006) Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med 231:in press
20. Egidy G, Peduto Eberl L, Valdenaire O, Irmler M, Majdi R, Diserens AC, Fontana A, Janzer RC, Pinet F, Juillerat-Jeanneret L (2000) The endothelin system in human glioblastoma. Lab Invest 80:1681-1689
21. Eberl L, Valdenaire O, Saintgiorgio V, Jeannin J, Juillerat-Jeanneret L (2000) Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer 86:182-187
22. Cruz A, Parnot C, Ribatti D, Corvol P, Gasc JM (2001) Endothelin-1, a regulator of angiogenesis in the chick chorioallantoic membrane. J Vasc Res 38:536-545
23. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25:2243-2278
24. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL (2005) Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11:12-20
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216